GUJTHEM · Concall Summary
GUJARAT THEMIS BIOSYN LTD
During the Q1 FY27 earnings conference call, management highlighted Gujarat Themis Biosyn Limited's (GTBL) strategic transformation into a diversified, innovation-driven pharmaceutical company. Dr. Sachin Patel, Managing Director, noted that the company is focusing on expanding its fermentation infrastructure and enhancing R&D capabilities to capture higher value opportunities in the pharmaceutical value chain. The company reported a 22.1% year-on-year increase in revenue from operations, reaching INR 43.8 crores, and a 49.4% growth in EBITDA to INR 20.8 crores. Management discussed two significant acquisitions: MicroBiopharm Japan, which adds advanced fermentation technologies, and a portfolio of 13 brands from Sanofi, enhancing GTBL's commercial presence. The call concluded with management emphasizing their commitment to disciplined execution and sustainable growth.
Management emphasized strategic growth initiatives and strong financial performance.
View source filing →Earlier concalls
- 2026-08-07 — Gujarat Themis Biosyn Limited (GTBL) reported a strong start to the financial year 2026-27, with a 22.1% year-on-year in…
- 2026-06-29 — Gujarat Themis Biosyn Limited (GTBL) provided an investor presentation detailing its recent acquisitions and strategic i…
- 2026-05-25 — Gujarat Themis Biosyn Limited (GTBL) reported a strong fiscal year-end performance, with sales volumes driven by resilie…
See GUJTHEM's full Research Pro page — annual report summary, insider trades, promoter pledge trend, options positioning and Ask-RedixFi AI.
Sign up free